Hypofractionated Stereotactic Radiotherapy Using Intensity-Modulated Radiotherapy in Patients with One or Two Brain MetastasesNarayana A.a · Chang J.b · Yenice K.b · Chan K.a · Lymberis S.a · Brennan C.c, d · Gutin P.H.c, d
Departments of aRadiation Oncology, bMedical Physics and cSurgery, Memorial Sloan Kettering Cancer Center, and dDepartment of Neurological Surgery, Weill Medical College of Cornell University, New York, N.Y., USA
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Purpose: A small fraction of patients with 1–2 brain metastases will not be suitable candidates to either surgical resection or stereotactic radiosurgery (SRS) due to either their location or their size. The objective of this study was to determine the local control, survival, patterns of relapse and the incidence of brain injury following a course of hypofractionated stereotactic radiotherapy while avoiding upfront whole brain radiation therapy (WBRT) in this subgroup of patients. Methods: A Gill-Thomas removable head frame system was used for immobilization. Brain LAB software with dynamic multileaf collimator hardware was used to design and deliver an intensity-modulated radiation therapy treatment plan. A dose of 600 cGy was prescribed to the 100% isodose line that would encompass the lesion with a 3-mm margin. A total dose of 3,000 cGy was delivered in 5 fractions using 2 fractions per week. The patients were followed with neurological examination and serial MRI images done every 3 months following the procedure. Results: Twenty patients have been treated using this fractionation schedule since April 2004. The 1-year local control at the site of original disease is 70%. The complete response, partial response and stable disease at the last follow-up were 15, 30 and 45%, respectively. Two patients had local recurrence at the site of original disease, while 5 had evidence of leptomeningeal disease. Two additional patients developed new brain metastases, resulting in a 1-year brain relapse-free survival of 36% following this approach. The median overall survival was 8.5 months. Three patients (15%) developed steroid dependency lasting 3 months or longer following the procedure. Four patients (20%) needed WBRT as salvage following this approach. Conclusions: The preliminary results of hypofractionated SRS are comparable to both surgery and SRS data for solitary brain metastases in terms of local control and overall survival with acceptable morbidity in this cohort of unfavorable patients.
© 2007 S. Karger AG, Basel
Narayana A, Leibel SA: Primary and metastatic brain tumors in adults; in Leibel S, Philips TL (eds): Textbook of Radiation Oncology, ed 2. Philadelphia, Saunders, 2004, p 471.
- Delattre JY, Krol G, Tahler HT, et al: Distribution of brain metastases. Arch Neurol 1988;45:741.
- Gaspar L, Scott C, Rotman M, et al: Recursive portioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997;37:745.
- Patchell RA, Tibbs PA, Walsh JW, et al: A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322:494.
- Moser R, Johnson M: Surgical management of brain metastases: How aggressive should be we? Oncology 1989;3:123.
- Chen JC, Petrovich Z, O’Day S, et al: Stereotactic radiosurgery in the treatment of metastatic disease to the brain. Neurosurgery 2000;47:268.
- Flickinger JC, Lunsford LD, Somaza S, et al: Radiosurgery: its role in brain metastasis management. Neurosurg Clin N Am 1996;7:497.
- Fukuoka S, Seo Y, Takanashi M: Radiosurgery of brain metastases with the Gamma Knife. Stereotact Funct Neurosurg 1996;66:193.
- Nakayama H, Tokuuye K, Komatsu Y, et al: Stereotactic radiotherapy for patients who initially presented with brain metastases from non-small cell carcinoma. Acta Oncol 2004;43:736–739.
- Ikushima H, Tokuuye K, Sumi M, et al: Fractionated stereotactic radiotherapy of brain metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys 2000;48:1389–1393.
- Gill SS, Thomas DG, Warrington AP, Brada M. Relocatable frame for stereotactic external beam radiotherapy. Int J Radiat Oncol Biol Phys 1991;20:599–603.
- Kooy HM, Dunbar SF, Tarbell NJ, et al: Adaptation and verification of the relocatable Gill-Thomas-Cosman frame in stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 1994;30:685–691.
- Cosgrove VP, Jahn U, Pfaender M, Bauer S, Budach V, Wurm RE: Commissioning of a micro multi-leaf collimator and planning system for stereotactic radiosurgery. Radiother Oncol 1999;50:325–336.
- Llacer J: Inverse radiation treatment planning using the Dynamically Penalized Likelihood method. Med Phys 1997;24:1751–1764.
- Noordijk EM, Vecht CJ, Haaxma-Reiche H: The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys 1994;29:711.
- Andrew DW, Scott CB, Sperduto PE, et al: Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTO 9508 randomized trial. Lancet 2004;363:1665.
- Aoyama H, Shirato H, Tago M, et al: Stereotactic radiosurgery plus whole brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006;295:2483.
- Cairncross JG, Kim JH, Posner JB: Radiation therapy for brain metastases. Ann Neurol 1980;7:529.
Moriarty TM, Loeffler JS, Black PM: Long-term follow-up of patients treated with sterotactic radiosurgery for single or multiple brain metastases; in Kondziolka D (ed): Radiosurgery. Basel, Karger, 1996, vol 1, pp 83–91.
- DeAngelis LM, Delattre JY, Posner JB: Radiation-induced dementia in patients cured of brain metastases. Neurology 1989;39:789.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.